Three‐year outcomes of peripheral blood mononuclear cells vs purified CD34+ cells in the treatment of angiitis‐induced no‐option critical limb ischemia and a cost‐effectiveness assessment: A randomized single‐blinded noninferiority trial
Abstract For patients with angiitis‐induced critical limb ischemia (AICLI), cell transplantation, such as purified CD34+ cells (PCCs) and peripheral blood mononuclear cells (PBMNCs), is gradually being used as a promising treatment. This was the first randomized single‐blinded noninferiority trial (...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-05-01
|
| Series: | Stem Cells Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/sctm.20-0033 |